Navigation Links
For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
Date:4/23/2013

BURLINGTON, Mass., April 23, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the numerous therapies in clinical development for extensive-disease small-cell lung cancer (ED-SCLC), no emerging therapy is likely to replace etoposide (Bristol-Myers Squibb's Etopophos/VePesid, generics)/carboplatin (generics) as the standard of care before 2022. Interviewed experts complain that treatment for SCLC has changed very little in decades, and—given the challenges of treating this aggressive disease and the current clinical pipeline—experts are pessimistic that the treatment landscape will improve in the near future.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled How Receptive Would Oncologists and Payers Be to Therapies That Partially Address the Unmet Needs of Patients with Advanced Disease? finds that surveyed U.S. and European oncologists agree that increasing overall survival (OS) is one of the greatest unmet needs in ED-SCLC. Despite high response rates with first-line therapy, most patients relapse within a year after treatment and survival rates remain dismal. Experts admit that, should efficacy benefits be seen with therapies in development—such as Ziopharm Oncology's Zymafos, Bristol-Myers Squibb's Yervoy, Genentech/Roche/Chugai's Avastin or Immunogen's lorvotuzumab mertansine—these benefits will likely be only incremental improvements that will not transform current treatment practice. According to the findings, a drug that offers marked improvement in survival presents a strong commercial opportunity to developers, although no drug in clinical development is expected to impart such substantial gains.

The report also finds that most surveyed managed care organization (MCO) pharmacy directors would consider reimbursing new therapies at a substantial premium to the current standard of care if such drugs can impart meaningful gains in survival relative to etoposide/carboplatin. Surveyed payers indicated that ED-SCLC therapies that impart an OS benefit could command price premiums as high as 20 times the cost of etoposide/carboplatin regimen and still be able to obtain reimbursement. This willingness to include premium-priced drugs on formulary reflects the dearth of therapies for ED-SCLC that improve survival relative to etoposide/carboplatin.

"A major problem in the treatment of ED-SCLC is the development of chemoresistant disease," said Decision Resources Senior Analyst Regina Jammen . "Finding therapies that can be used upfront for newly diagnosed patients that do not induce resistance would be a real benefit to patients. Such a therapy would likely not provide a cure but oncologists and patients alike would value new therapies that extend survival beyond what we are seeing now. It is reassuring to know that payers would accept substantial price increases over current treatments for innovative therapies and would include them on formulary, even if cost controls slow uptake of these potential new therapies."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering.  The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)... 2016  The global biosurgery market is expected to ... period of 2016 to 2021. The market is poised ... 18.21 billion in 2016. The market is primarily driven ... related injuries and spinal problems, increasing clearance of biosurgery ... blood loss management. In this report, the ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... The West Virginia Medical Institute (WVMI) ... The name change aligns the entire company with its existing Quality Insights branded ... “We are very proud of the achievements associated with the West Virginia Medical ...
(Date:12/8/2016)... ... 2016 , ... Russ DiGilio , founder and owner ... campaign which supported local breast cancer organizations during National Breast Cancer Awareness Month ... initiative, and we’re very pleased with the participation in every franchisee’s community,” ...
(Date:12/8/2016)... ... 2016 , ... Mirixa Corporation , a leading healthcare ... patient care services, has announced the promotions of Karen Litsinger to senior vice ... sales. , Litsinger joined Mirixa in 2008 after serving as a partner ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
Breaking Medicine News(10 mins):